Samuel A. Funt, MD
Genitourinary Medical Oncologist
My Role at MSKWe post reviews for MSK healthcare providers who have at least 30 patient experience surveys completed. If you do not see reviews for a provider, it may be because they do not yet have enough survey responses, or the provider may not be part of the group of healthcare providers included in the survey.
Only outpatient providers are included in the survey. Healthcare providers who only work in the hospital or in urgent care are not included in the survey. Pathologists or researchers who do not provide direct care to patients do not have reviews.
Areas of Expertise
My Specialties
- Genitourinary Malignancies
- Bladder Cancer: Testicular Cancer (Germ Cell Tumors)
Request an Appointment
About Me
- Assistant Attending Physician
I am a medical oncologist who cares for people with genitourinary cancer. I specialize in treating bladder cancer (urothelial carcinoma) and testicular cancer (germ cell tumors).
I care for hundreds of people with genitourinary cancer each year. Early on in my training, I understood how meaningful and rewarding it is to have trusting relationships with the people in my care. I learned that every patient has a unique medical and social history and each cancer has a particular genetic profile that allows for an increasingly personalized approach to care. At that point, I knew that a career in cancer care would allow me to practice both the art and science of medicine at the highest level.
Read more
Immunotherapy has revolutionized how we care for people with bladder cancer. Most people don’t respond to immunotherapy, however, and we can’t tell ahead of time who will. My research focuses on improving outcomes for people with bladder cancer by leading clinical trials testing immunotherapies. I am also working to develop immune-related biomarkers that can predict who will benefit.
Unfortunately, some men with advanced testicular cancer do not respond to chemotherapy and their disease progresses. These are often young adults in the prime of their lives. To help this group, I am investigating ways to help predict resistance or sensitivity to chemotherapy before treatment begins. I am also studying the effectiveness of immunotherapy in people with relapsed and refractory testicular cancer.
Patients and their caregivers have a universal desire for specialists who listen and respond to their specific concerns about how their diagnosis will affect their everyday life. These can range from managing pain to being well enough to enjoy special events, like a loved one’s wedding or the birth of a grandchild. My goal is to help patients feel confident that my team and I have their best interests in mind and truly care about all aspects of their well-being.
Outside of work, I love spending time with my wife and two young children.
A genitourinary (jeh-nih-toh-YOOR-ih-nayr-ee) medical oncologist is a cancer doctor who specializes in genitourinary (GU) cancers. This includes bladder, kidney, penis, prostate, and testicular cancers.
My Specialties
- Genitourinary Malignancies
- Bladder Cancer: Testicular Cancer (Germ Cell Tumors)
Education
- MD, Emory University
Residencies
- Internal Medicine - New York Presbyterian/Columbia University Medical Center
Awards and Honors
- Alpha Omega Alpha
- Columbia Univeristy Medical Center John N. Loeb Intern Award
- selected by ASCO/AACR to attend its Methods in Clinical Cancer Research workshop
- Conquer Cancer Foundation’s Young Investigator Award
- Bladder Cancer Advocacy Network’s John Quale Travel Fellowship
- Bochner-Fleisher Research Scholar in Urologic Oncology at Memorial Sloan Kettering Cancer Center
- National Cancer Institute’s K12 Paul Calabresi Career Development Award for Clinical Oncology
Fellowships
- Medical Oncology - Memorial Sloan Kettering Cancer Center
Board Certifications
- Internal Medicine
- Medical Oncology
Insurance Information
Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.
In Network Coverage Type
HMO, PPO
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
HMO, EPO PPO, POS
In Network Coverage Type
PPO, POS, EPO, HMO
Offers a qualified health plan from the Health Insurance Marketplace. Call Emblem to learn more.
In Network Coverage Type
PPO, HMO
In Network Coverage Type
PPO, HMO, DSN
In Network Coverage Type
PPO
In Network Coverage Type
HMO, EPO
Offers a qualified health plan from the Health Insurance Marketplace. Call Fidelis to learn more.
In Network Coverage Type
EPO, HMO, PPO, POS
Offers a qualified health plan from the Health Insurance Marketplace. Call Healthfirst to learn more.
In Network Coverage Type
HMO
In Network Coverage Type
PPO
In Network Coverage Type
EPO
In Network Coverage Type
EPO
In Network Coverage Type
Federal Government
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
State Government
Don't see your carrier or plan? We can help you understand your coverage.
If you don't have health insurance or are worried that your care may not be fully covered, our financial assistance programs may be able to help.
If you have questions about insurance, call us at 646-497-9176.
Make an Appointment
New Patients
Current Patients
Contact and Location
Dr. Funt sees patients at one location.
Looking to see a doctor at a different location? See all MSK locations.
Colleagues
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.
Clinical Trials
- Clinical Trials Investigated by Dr. Funt
- A Phase 1/2 Study of Combination Drug Treatments for People With Urothelial Carcinoma
- A Phase I Study of ALX148 Immunotherapy plus Enfortumab Vedotin and/or Other Anticancer Therapies in People with Advanced Urothelial Cancer
- A Phase II Study of Ipilimumab and Nivolumab Immunotherapy plus Cabozantinib to Treat Rare Advanced Genitourinary Cancers
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Search clinical trialsResearch and Publications
Visit PubMed for a full listing of Dr. Funt’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
See all on PubMedPatient Reviews
Your trust is our main concern
We strive to keep reviews trustworthy, honest and fair. Learn more about our patient experience reviews.
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Samuel A. Funt discloses the following relationships and financial interests:
-
76Bio, Inc.
Equity -
Allogene Therapeutics
Equity -
BioNTech
Professional Services and Activities -
ByHeart, Inc.
Equity -
Doximity, Inc.
Equity -
IconOVir Bio, Inc.
Equity
-
Immunai Inc.
Professional Services and Activities (Uncompensated) -
Kronos Bio, Inc
Equity -
Merck Sharp & Dohme
Professional Services and Activities -
Neogene Therapeutics Inc
Equity -
UroGen Pharma, Inc.
Equity -
Vida Ventures, LLC
Equity
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2023 through disclosure submission in spring 2024). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].
